Development of oncological therapeutic agents: Current state and outlook with special regard to the situation in Germany;Arzneimittelentwicklung in der onkologie: Status und ausblick unter besonderer berucksichtigung des standortes Deutschland

Arzneimittel-Forschung/Drug Research

Volumn 50, Issue 10, 2000, Pages 946-953

  Brock, N ^a   Pohl, J ^a  

^a NONE   (Germany)

Author keywords

Cancer chemotherapy; Oncological therapeutic agents, development, situation in Germany

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; AZIRIDINE DERIVATIVE; CETRORELIX; CYCLOPHOSPHAMIDE; GLUFOSFAMIDE; GONADORELIN ANTAGONIST; IFOSFAMIDE; MAFOSFAMIDE; MESNA; MILTEFOSINE; TRIAZIQUONE; TROFOSFAMIDE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CHEMOTHERAPY; CANCER RESEARCH; CLINICAL TRIAL; DRUG METABOLISM; DRUG SAFETY; GERMANY; HISTORY OF MEDICINE; HUMAN; HUMAN CELL; HUMAN TISSUE; PHASE 2 CLINICAL TRIAL;

EID: 0033787401     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1300308     Document Type: Article

References (51)

1. Inhibition of folate biosynthesis and function as a basis for chemotherapy
2. Experimentelle grundlagen der chemotherapie des krebses
3. Ideas and reality in the development of cancer chemotherapeutic agents, with particular reference to oxazaphosphorine cytostatics
4. Chemotherapeutic action of a cyclic nitrogen mustard phosphamide ester (B 518-Asta)
5. Zur pharmakologischen charakterisierung zyklischer N-Lost-Phosphamidester als Krebs-Chemotherapeutika
6. Uber beziehungen zwischen chemischer konstitution und cancerotoxischer wirkung in der reihe der phosphamidester des Bis-(β-chlorathyl)-amins
7. Pharmacologic characterization of cyclophosphamide (NSC-26271) and cyclophosphamide metabolites
8. Pharmakologische untersuchungen mit trofosfamid (Ixoten®), einem neuen oxazaphosphorinoxid
9. The special position of ifosfamide in the series of cytostatically active oxazaphosphorine
10. Die aktivierung von ifosfamid an mensch und tier
11. Oxazaphosphorine cytostatics: Structure-activity relationships, selectivity and metabolism, regional detoxification
12. Ifosfamide - Dosing and scheduling
13. Two oral trofosfamide schedules in elderly patients with refractory non-Hodgkin's lymphoma
14. Tumor growth control by oral trofosfamide in patients with metastatic breast cancer
15. Konzeption und wirkmechanismus von uromitexan (Mesna)
16. Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention. I. Experimental studies on the urotoxicity of alkylating compounds
17. Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention. II. Comparative study on the urotoxicity efficacy of thiols and other sulfur compounds
18. Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention. III. Profile of action of sodium 2-mercaptoethane sulfonate (Mesna)
19. Mesna (Natrium-2-Mercaptoethansulfonat). Prophylaxe der akuten urotoxischen nebenwirkungen sowie der kanzerogenen spatfolgen von cyclophosphamid und ifosfamid
20. The problem of specificity and selectivity of alkylating cytostatics: Studies on N-2-chloroethyl-amido-oxazaphosphorines
21. The problem of oncostatic specificity of cyclophosphamide (NSC-26271): Studies on reactions that control the alkylating and cytotoxic activity
22. Metabolism and pharmacokinetic behaviour of cyclophosphamide and related oxazaphosphorines
23. Stabilized primary metabolites of oxazaphosphorine cytostatics with high cytotoxic specificity and cancerotoxic selectivity needing no enzymatic activation
24. Intrathecal mafosfamide therapy for pediatric brain tumors with meningeal dissemination
25. Basis and new developments in the field of oxazaphosphorines
26. Overview on the clinical development of Miltefosine solution (Miltex) for the treatment of cutaneous breast cancer
27. D-19575 - A sugar-linked isophosphoramide mustard derivative exploiting trans-membrane glucose transport
28. Luteinizing hormone-releasing-hormone antagonist Cetrorelix as primary single therapy in patients with advanced prostatic cancer and paraplegia due to metastatic invasion of spinal cord
29. Die bestimmung der therapeutischen breite von arzneimitteln
30. Pharmakologische charakterisierung von arzneimitteln mit hilfe des therapeutischen index
31. A screening system for anticancer agents based on the therapeutic index
32. Models and methods for the assessment of cumulation of drug effects
33. Experimental basis of cancer chemotherapy
34. Zur ernahrung der laboratoriumstiere. 1. Mitteilung
35. 2. Mitteilung
36. Vorlaufige klinische beobachtungen mit einem neuen N-Lost-Phosphamidester in der tumortherapie
37. Experimental screening procedures and clinical predictability value
38. Antitumor activity of cytoxan
39. Neue experimentelle ergebnisse mit N-Lost-Phosphamidestern
40. Ifosfamide. Pharmacology, safety and therapeutic potential
41. Therapeutic effects of single-push or fractionated injections of cyclophosphamide or ifosfamide combined with mesna
42. Efficacy of ifosfamide in refractory malignant disease and uroprotection by mesna: Results of a clinical phase II-study with 1512 patients
43. Ifosfamide in refractory male germ cell tumors
44. Arzneimittelentwicklung und -testung fur die krebstherapie, ein kooperatives forschungsprogramm der bundesregierung
45. Arzneimittelentwicklung in Deutschland
46. Arzneimittelentwicklung in der onkologie - Status und ausblick unter besonderer berucksichtigung des standortes Deutschland